tickstock newsroom AI
Articles
Predator Oil & Gas raises £3m to deepen Snowcap‑3 and progress Corrib South workstream
It will fund deeper drilling at Snowcap‑3, Trinidad well reactivations, Moroccan long‑lead inventory and an updated Corrib South technical package.
ValiRx raises up to £1.155m to fund McGill in‑licence, Cytolytix preclinical work and animal‑health expansion
"We believe the current valuation does not fully reflect the breadth of assets, intellectual property and commercial optionality within the Group, and this fundraising is designed to help unlock several potential near‑term catalysts," Mark Eccleston.
Valereum raises £1.05m to scale up VLRM Markets
The funds are expected to help the digital assets firm expand distribution for its VLRM Markets platform.
Zanaga raises £5.7m to accelerate Zanaga Project workstreams
The mine developer raised gross proceeds of £5.7m through a placing, subscription and retail offer at 4p per share to provide additional working capital headroom and accelerate workstreams on the Zanaga Project.
Ajax Resources extends exclusivity on Paguanta acquisition to 14 August
It has extended exclusivity over the proposed purchase of the Paguanta silver‑dominant polymetallic project in Chile until 14 August while it finalises the sale and purchase agreement with Asara Resources.
GSK lands expanded approval for RSV vaccine Arexvy in Japan
"This expanded approval, the first covering all at-risk adults in Japan, can help reduce potentially severe outcomes of RSV," said Sanjay Gurunathan.
AstraZeneca secures US approval for blood pressure drug Baxfendy
"The nearly double‑digit placebo‑adjusted systolic blood pressure reduction achieved with Baxfendy is exciting and clinically meaningful for clinicians and patients," Dr Bryan Williams
Kainos eyes £100m ARR as FY26 revenue climbs 17%
It said Workday Products will hit £100m of annual recurring revenue by the end of 2026 after reporting group revenue for the year ended 31 March of £431.1m, up 17% year‑on‑year.
Anglo American agrees sale of Australian steelmaking coal assets for up to US$3.875bn
It will receive US$2.3bn upfront and an earnout of up to US$1.575bn for the Australian steelmaking coal portfolio, with completion expected by the first quarter of 2027.
AstraZeneca's breast cancer drug Enhertu cleared by FDA
"These approvals mark an important step forward, expanding the possibility of cure to more patients for the first time in many years and positioning Enhertu as a foundational treatment in early breast cancer," said Dave Fredrickson
Glencore notes Chile tribunal sets aside Collahuasi environmental authorisation
Capita highlights revenue growth in early 2026
Adjusted revenue rose 2.9% in the four months to 30 April, in line with expectations, and the private-sector contact centre sale to Inspirit is expected to complete ahead of its H1 results.
Metals One expands DISA deal to treat uranium waste at Uravan Project
It has expanded an agreement with DISA Technologies to evaluate and treat eight abandoned uranium waste dumps at its 100%-owned Uravan Project in Colorado, securing a sliding 2.5-4.0% gross revenue share of recovered concentrates with no capex or opex exposure.
Physiomics extends CEO Peter Sargent's tenure
Peter Sargent has agreed to extend his existing agreement and will remain in his current role throughout June 2026.
Centrica to pay £20m to Ofgem, plans up to £70m of debt write-offs
The British Gas owner will pay £20m into Ofgem’s Voluntary Redress Fund, review prepayment meter records dating back to 2018 and write off up to £70m of energy debt for vulnerable customers.
Union Jack Oil's Crossroads well hits multiple hydrocarbon zones, testing set for mid‑June
The Crossroads well in Oklahoma logged multiple hydrocarbon shows and will be tested in the coming weeks.
Landsec expects like‑for‑like net rent to grow c.3-5% in FY27
"We are well placed to deliver an acceleration in EPS growth," said chief executive Mark Allan.
Spire Healthcare receives 250p per-share takeover proposal from Toscafund
Spire Healthcare Group has received a non-binding proposal from funds advised by Toscafund for a possible cash offer of 250p per share, with an option for shareholders to elect an unlisted rollover equity alternative.
Future H1 revenue and earnings fall as programmatic advertising and affiliate marketing hit
Revenue fell 8% year‑on‑year to £349.1m and adjusted EBITDA declined 24% to £83.3m in the half‑year to 31 March.